JP2011513431A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011513431A5 JP2011513431A5 JP2010549910A JP2010549910A JP2011513431A5 JP 2011513431 A5 JP2011513431 A5 JP 2011513431A5 JP 2010549910 A JP2010549910 A JP 2010549910A JP 2010549910 A JP2010549910 A JP 2010549910A JP 2011513431 A5 JP2011513431 A5 JP 2011513431A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- compound
- cyano
- acceptable salt
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 2 -n- hexyl Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- DLIDOWKXQKFZIN-IKABJYOBSA-N (2s)-2-[[(3s)-7-benzoyl-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-2-oxo-1,6,8,9-tetrahydropyrido[4,3-g][1,4]benzoxazine-8-carbonyl]amino]-3-[4-(4-cyanophenyl)phenyl]propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C1N(CC2=CC=3O[C@H](C(=O)NC=3C=C2C1)C=1C=CC(OCC=2C=C(Cl)C(Cl)=CC=2)=CC=1)C(=O)C=1C=CC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C=C1 DLIDOWKXQKFZIN-IKABJYOBSA-N 0.000 claims 1
- WWEDIOLJVSBYRU-IKABJYOBSA-N (2s)-3-[4-(4-cyanophenyl)phenyl]-2-[[(3s)-3-[4-[(3,4-dichlorophenyl)methoxy]phenyl]-2-oxo-7-(pyridin-2-ylmethyl)-1,6,8,9-tetrahydropyrido[4,3-g][1,4]benzoxazine-8-carbonyl]amino]propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)C1N(CC2=CC=3O[C@H](C(=O)NC=3C=C2C1)C=1C=CC(OCC=2C=C(Cl)C(Cl)=CC=2)=CC=1)CC=1N=CC=CC=1)C(C=C1)=CC=C1C1=CC=C(C#N)C=C1 WWEDIOLJVSBYRU-IKABJYOBSA-N 0.000 claims 1
- 125000001140 1,4-phenylene group Chemical group [H]C1=C([H])C([*:2])=C([H])C([H])=C1[*:1] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 0 *C(*)N(*)C(C(Cc1c2)N(*)Cc1cc(OC1*)c2N(*)C1=O)=O Chemical compound *C(*)N(*)C(C(Cc1c2)N(*)Cc1cc(OC1*)c2N(*)C1=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3459908P | 2008-03-07 | 2008-03-07 | |
| US61/034,599 | 2008-03-07 | ||
| PCT/US2009/036333 WO2009111700A2 (en) | 2008-03-07 | 2009-03-06 | Oxadiazoanthracene compounds for the treatment of diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011513431A JP2011513431A (ja) | 2011-04-28 |
| JP2011513431A5 true JP2011513431A5 (enExample) | 2013-02-14 |
| JP5382952B2 JP5382952B2 (ja) | 2014-01-08 |
Family
ID=41056666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010549910A Active JP5382952B2 (ja) | 2008-03-07 | 2009-03-06 | 糖尿病の治療のためのオキサジアゾアントラセン化合物 |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7727983B2 (enExample) |
| EP (1) | EP2262364B1 (enExample) |
| JP (1) | JP5382952B2 (enExample) |
| KR (1) | KR101616737B1 (enExample) |
| CN (1) | CN101959405B (enExample) |
| AU (1) | AU2009221722B2 (enExample) |
| BR (1) | BRPI0910282A2 (enExample) |
| CA (1) | CA2716664C (enExample) |
| DK (1) | DK2262364T3 (enExample) |
| EA (1) | EA018225B1 (enExample) |
| ES (1) | ES2567451T3 (enExample) |
| IL (1) | IL207570A (enExample) |
| MA (1) | MA32175B1 (enExample) |
| MX (1) | MX2010009752A (enExample) |
| NZ (1) | NZ587343A (enExample) |
| WO (1) | WO2009111700A2 (enExample) |
| ZA (1) | ZA201006367B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009221722B2 (en) * | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
| EA023430B1 (ru) | 2009-03-30 | 2016-06-30 | виТиви ТЕРАПЬЮТИКС ЭлЭлСи | Замещенные производные азоантрацена, фармацевтические композиции и способы их применения |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| DE102010015123A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi-Aventis Deutschland Gmbh | Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| RU2013127611A (ru) | 2010-12-23 | 2015-01-27 | Пфайзер Инк. | Модуляторы глюкагонового рецептора |
| WO2012096824A1 (en) * | 2011-01-12 | 2012-07-19 | Transtech Pharma, Inc. | Phenylglyoxylic acid derivatives and their preparation and use |
| MX2013009140A (es) | 2011-02-08 | 2013-10-01 | Pfizer | Moduladores del receptor de glucagon. |
| RU2013157388A (ru) | 2011-07-22 | 2015-08-27 | Пфайзер Инк. | Хинолинильные модуляторы глюкагонового рецептора |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013045413A1 (en) | 2011-09-27 | 2013-04-04 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| JP2015510947A (ja) * | 2012-03-22 | 2015-04-13 | トランステック・ファーマ,エルエルシー | 小分子glp1rアゴニストのトリス(ヒドロキシメチル)アミノメタン塩ならびにその医薬組成物および使用 |
| IN2015DN03795A (enExample) | 2012-10-24 | 2015-10-02 | Inserm Inst Nat De La Santé Et De La Rech Médicale | |
| CN104968341B (zh) | 2013-01-17 | 2020-06-09 | Vtv治疗有限责任公司 | Glp1r激动剂和二甲双胍的组合及其在制备治疗2型糖尿病和其他障碍的药物中的用途 |
| CA2955836C (en) * | 2014-07-25 | 2023-02-14 | Celgene International Ii Sarl | Glp-1 receptor modulators |
| US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
| JOP20190060A1 (ar) | 2016-09-26 | 2019-03-26 | Chugai Pharmaceutical Co Ltd | مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1 |
| TW201925204A (zh) * | 2017-11-22 | 2019-07-01 | 日商第一三共股份有限公司 | 稠合三環化合物 |
| KR20210005843A (ko) | 2018-05-08 | 2021-01-15 | 브이티브이 테라퓨틱스 엘엘씨 | Glp1r 작용제의 치료적 용도 |
| EA202191432A1 (ru) | 2018-11-22 | 2021-10-14 | Цилу Регор Терапьютикс Инк. | Агонисты glp-1r и их применения |
| WO2020207474A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
| CN115315426B (zh) | 2020-04-01 | 2023-12-12 | 杭州中美华东制药有限公司 | Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法 |
| EP4130005A4 (en) | 2020-04-01 | 2024-04-24 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF |
| TW202144340A (zh) | 2020-04-03 | 2021-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合咪唑類衍生物、其製備方法及其在醫藥上的應用 |
| TW202210461A (zh) * | 2020-05-28 | 2022-03-16 | 中國大陸商杭州中美華東製藥有限公司 | 一種(s)—2—胺基—3—(4—(2,3—二甲基吡啶—4—基)苯基)丙酸甲酯二酸鹽的製備方法 |
| EP4159737A4 (en) * | 2020-05-28 | 2024-10-09 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | METHOD FOR PREPARING A GLP-1 RECEPTOR AGONIST-FREE BASE |
| JP2023539584A (ja) | 2020-09-01 | 2023-09-15 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 縮合イミダゾール誘導体、その調製方法及びその医薬的応用 |
| WO2022078152A1 (zh) | 2020-10-12 | 2022-04-21 | 杭州中美华东制药有限公司 | 苯并咪唑酮类glp-1受体激动剂及其用途 |
| US20230382899A1 (en) * | 2020-10-14 | 2023-11-30 | Qilu Regor Therapeutics Inc. | Crystal forms of glp-1r agonists and uses thereof |
| EP4247804A1 (en) | 2020-11-20 | 2023-09-27 | Gilead Sciences, Inc. | Polyheterocyclic glp-1 r modulating compounds |
| CA3200245A1 (en) | 2020-11-27 | 2022-06-02 | Junjun Wu | Benzimidazole derivative and preparation method therefor and medical use thereof |
| CN116940561A (zh) | 2021-03-22 | 2023-10-24 | 杭州中美华东制药有限公司 | 噻吩类glp-1受体激动剂及其用途 |
| EP4317145A4 (en) | 2021-03-24 | 2025-03-12 | Shionogi & Co., Ltd | Pharmaceutical composition containing glp-1 receptor agonist having fused ring |
| WO2022262615A1 (zh) * | 2021-06-17 | 2022-12-22 | 杭州中美华东制药有限公司 | 蒽类化合物、其制备方法和医药用途 |
| AU2022300055A1 (en) | 2021-06-24 | 2024-01-18 | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | Glp-1 receptor agonist and composition and use thereof |
| CN115521320B (zh) * | 2021-06-25 | 2023-09-05 | 沈阳兴齐眼药股份有限公司 | 一种制备普拉洛芬的方法 |
| WO2024063143A1 (ja) | 2022-09-22 | 2024-03-28 | 塩野義製薬株式会社 | Glp-1受容体アゴニスト作用を有する縮合環化合物 |
| CN120981457A (zh) | 2023-09-14 | 2025-11-18 | 歌礼制药(中国)有限公司 | Glp-1r激动剂及其治疗方法 |
| US12291530B1 (en) | 2023-11-24 | 2025-05-06 | Ascletis Pharma (China) Co., Limited | GLP-1R agonist and therapeutic method thereof |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| WO2025189141A1 (en) | 2024-03-08 | 2025-09-12 | Annapurna Bio, Inc. | Methods for treating obesity and increasing weight loss |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6345270A (ja) * | 1986-02-11 | 1988-02-26 | Takeda Chem Ind Ltd | 1,4−ベンゾオキサジン誘導体,その製造法およびそれを含有する医薬用組成物 |
| EP0233728A1 (en) | 1986-02-11 | 1987-08-26 | Takeda Chemical Industries, Ltd. | 1,4-Benzoxazine derivatives their production and use |
| EP0873295B1 (en) * | 1995-10-06 | 2003-04-02 | Ligand Pharmaceuticals, Inc. | Dimer-selective rxr modulators and methods for their use |
| EP1147094A1 (en) * | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| WO2001040192A1 (en) * | 1999-12-03 | 2001-06-07 | Kyoto Pharmaceutical Industries, Ltd. | Novel heterocyclic compounds and salts thereof and medicinal use of the same |
| EP1125925A1 (en) * | 2000-02-15 | 2001-08-22 | Applied Research Systems ARS Holding N.V. | Amine derivatives for the treatment of apoptosis |
| US20050222036A1 (en) | 2000-08-24 | 2005-10-06 | Thomas Jefferson University | Peptide compositions with effects on blood glucose |
| ATE435210T1 (de) * | 2003-03-26 | 2009-07-15 | Actelion Pharmaceuticals Ltd | Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten |
| AU2009221722B2 (en) * | 2008-03-07 | 2014-12-18 | Vtv Therapeutics Llc | Oxadiazoanthracene compounds for the treatment of diabetes |
| EP2579888A2 (en) | 2010-06-09 | 2013-04-17 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
-
2009
- 2009-03-06 AU AU2009221722A patent/AU2009221722B2/en active Active
- 2009-03-06 WO PCT/US2009/036333 patent/WO2009111700A2/en not_active Ceased
- 2009-03-06 CA CA2716664A patent/CA2716664C/en active Active
- 2009-03-06 CN CN200980108115.XA patent/CN101959405B/zh active Active
- 2009-03-06 BR BRPI0910282-5A patent/BRPI0910282A2/pt not_active Application Discontinuation
- 2009-03-06 KR KR1020107020688A patent/KR101616737B1/ko not_active Expired - Fee Related
- 2009-03-06 EA EA201071045A patent/EA018225B1/ru not_active IP Right Cessation
- 2009-03-06 DK DK09718287.7T patent/DK2262364T3/en active
- 2009-03-06 NZ NZ587343A patent/NZ587343A/en not_active IP Right Cessation
- 2009-03-06 US US12/399,504 patent/US7727983B2/en active Active
- 2009-03-06 ES ES09718287T patent/ES2567451T3/es active Active
- 2009-03-06 JP JP2010549910A patent/JP5382952B2/ja active Active
- 2009-03-06 MX MX2010009752A patent/MX2010009752A/es active IP Right Grant
- 2009-03-06 EP EP09718287.7A patent/EP2262364B1/en active Active
-
2010
- 2010-04-13 US US12/759,010 patent/US7790714B2/en active Active
- 2010-08-03 US US12/849,225 patent/US7906507B2/en active Active
- 2010-08-12 IL IL207570A patent/IL207570A/en active IP Right Grant
- 2010-08-31 US US12/872,580 patent/US8524708B2/en not_active Expired - Fee Related
- 2010-09-10 ZA ZA2010/06367A patent/ZA201006367B/en unknown
- 2010-09-30 MA MA33212A patent/MA32175B1/fr unknown
-
2013
- 2013-08-01 US US13/956,578 patent/US8703766B2/en not_active Expired - Fee Related
-
2014
- 2014-03-05 US US14/197,771 patent/US8933222B2/en active Active
- 2014-12-01 US US14/556,837 patent/US9120813B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011513431A5 (enExample) | ||
| KR101276449B1 (ko) | 치료제로서의 치환된 감마 락탐 | |
| KR101367553B1 (ko) | 12-아릴 프로스타글란딘 유사체 | |
| JP5525500B2 (ja) | 1h−キナゾリン−2,4−ジオンおよびampa受容体リガンドとしてのそれらの使用 | |
| WO2013158649A1 (en) | Compositions and methods of modulating 15-pgdh activity | |
| AU2004240649A1 (en) | Immunosuppressant compounds and compositions | |
| CN114555574A (zh) | 靶向醛酮还原酶1c3的苯并二氢吡喃类化合物 | |
| JP2009541340A (ja) | 治療用化合物 | |
| US20070203222A1 (en) | Substituted gamma lactams as therapeutic agents | |
| JP2009534398A5 (enExample) | ||
| JP2010528089A5 (enExample) | ||
| JP2010513435A5 (enExample) | ||
| AU2003240714B2 (en) | Bis-aromatic alkanols | |
| CN109996797B (zh) | 作为乳酸脱氢酶的抑制剂的1h-吡唑-1-基-噻唑及其使用方法 | |
| JP5410438B2 (ja) | 治療用置換ラクタム類 | |
| JP2005520814A (ja) | HMG−CoA還元酵素阻害剤の製造法 | |
| JP5501760B2 (ja) | 治療薬としての置換ガンマラクタム類 | |
| EP2170345A1 (en) | Therapeutic substituted cyclopentanes for reducing intraocular pressure | |
| JP2010516778A (ja) | 治療薬としての置換アリールシクロペンテン類 | |
| US20040176614A1 (en) | Process for the preparation of indole derivatives and intermediates of the process | |
| CN101119747A (zh) | 组织因子产生抑制剂 | |
| KR20100087931A (ko) | 로슈바스타틴의 전구체 및 그의 제조 방법 | |
| CN105399737B (zh) | 噁唑烷酮类化合物及其用途 | |
| TW202246204A (zh) | 苯酚衍生物及其在醫藥上的應用 | |
| CA2787914C (en) | Therapeutic agents for treatment of ocular hypertension |